[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Citius Oncology Inc (CTOR)

Citius Oncology Inc (CTOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 68,806
  • Shares Outstanding, K 92,981
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,760 K
  • EBIT $ -39 M
  • EBITDA $ -24 M
  • 60-Month Beta 3.48
  • Price/Sales 10.10
  • Price/Cash Flow N/A
  • Price/Book 2.07
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.47
  • Most Recent Earnings $-0.27 on 05/15/26
  • Next Earnings Date 12/22/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5125 +44.39%
on 07/27/26
0.9350 -20.86%
on 08/14/26
+0.0511 (+7.42%)
since 07/17/26
3-Month
0.5125 +44.39%
on 07/27/26
0.9350 -20.86%
on 08/14/26
-0.2233 (-23.18%)
since 05/15/26
52-Week
0.4912 +50.65%
on 03/30/26
2.2500 -67.11%
on 10/16/25
-0.9500 (-56.21%)
since 08/15/25

Most Recent Stories

More News
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

$7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR ®

CTXR : 0.5620 (-25.62%)
CTOR : 0.7400 (-18.66%)
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

CRANFORD, N.J. , Aug. 12, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals,...

CTXR : 0.5620 (-25.62%)
CTOR : 0.7400 (-18.66%)
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

New institutional accounts ordering LYMPHIR increased 78% quarter over quarter

CTXR : 0.5620 (-25.62%)
CTOR : 0.7400 (-18.66%)
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption

Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. by August

CTXR : 0.5620 (-25.62%)
CTOR : 0.7400 (-18.66%)
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies

Investigator-initiated study data presented May 30, 2026, at the American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated durable responses and manageable tolerability in heavily pre-treated...

CTXR : 0.5620 (-25.62%)
CTOR : 0.7400 (-18.66%)
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting

24% Objective Response Rate, with an average of 21.1 month Duration of Response in responders, and favorable safety profile signals potential of LYMPHIR to augment immune checkpoint inhibitor efficacy

CTXR : 0.5620 (-25.62%)
CTOR : 0.7400 (-18.66%)
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

$5.6 Million in net revenue for the first half of fiscal 2026 from ongoing launch of LYMPHIR ®

CTXR : 0.5620 (-25.62%)
CTOR : 0.7400 (-18.66%)
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

$5.6 million in net revenue for the first half of fiscal 2026 as LYMPHIR ® launch progresses Up to $36.5 million in debt and equity capital secured Broad...

CTXR : 0.5620 (-25.62%)
CTOR : 0.7400 (-18.66%)
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization

Avenue Capital Group to provide up to $25 Million via Senior Credit Facility with an initial $10 million tranche funded at closing; additional tranches subject to certain conditions

CTOR : 0.7400 (-18.66%)
Citius Oncology Ships First International Order of LYMPHIR™ to Europe

Order fulfilment expands international patient access to LYMPHIR following initial U.S. launch

CTXR : 0.5620 (-25.62%)
CTOR : 0.7400 (-18.66%)

Business Summary

Citius Oncology Inc. platform to develop and commercialize novel targeted oncology therapies. The company is seeking approval from the U.S. Food and Drug Administration of LYMPHIR(TM) for an orphan indication in the treatment of persistent or recurrent cutaneous T-cell lymphoma, a rare form of non-Hodgkin...

See More

Key Turning Points

3rd Resistance Point 0.8623
2nd Resistance Point 0.8219
1st Resistance Point 0.7810
Last Price 0.7400
1st Support Level 0.6997
2nd Support Level 0.6593
3rd Support Level 0.6184

See More

52-Week High 2.2500
Fibonacci 61.8% 1.5781
Fibonacci 50% 1.3706
Fibonacci 38.2% 1.1631
Last Price 0.7400
52-Week Low 0.4912

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.